NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus
Clinical trials of BAFF blockade with belimumab have shown partial efficacy for the treatment of systemic lupus erythematosus (SLE), so other therapeutic options are required. Here, the authors present a new small molecule inhibitor that targets NIK with a similar efficacy to BAFF inhibition in two...
Guardado en:
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c1b21708fc0a4c58b4c58242d9d32c50 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:c1b21708fc0a4c58b4c58242d9d32c50 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:c1b21708fc0a4c58b4c58242d9d32c502021-12-02T15:34:46ZNF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus10.1038/s41467-017-02672-02041-1723https://doaj.org/article/c1b21708fc0a4c58b4c58242d9d32c502018-01-01T00:00:00Zhttps://doi.org/10.1038/s41467-017-02672-0https://doaj.org/toc/2041-1723Clinical trials of BAFF blockade with belimumab have shown partial efficacy for the treatment of systemic lupus erythematosus (SLE), so other therapeutic options are required. Here, the authors present a new small molecule inhibitor that targets NIK with a similar efficacy to BAFF inhibition in two mouse models of SLE.Hans D. BrightbillEric SutoNicole BlaquiereNandhini RamamoorthiSwathi Sujatha-BhaskarEmily B. GogolGeorgette M. CastanedoBenjamin T. JacksonYoungsu C. KwonSusan HallerJustin LeschKarin BentsChristine EverettPawan Bir KohliSandra LingeLaura ChristianKathy BarrettAllan JaochicoLeonid M. BerezhkovskiyPeter W. FanZora ModrusanKelli VelizMichael J. TownsendJason DeVossAdam R. JohnsonRobert GodemannWyne P. LeeCary D. AustinBrent S. McKenzieJason A. HackneyJames J. CrawfordSteven T. StabenMoulay H. Alaoui IsmailiLawren C. WuNico GhilardiNature PortfolioarticleScienceQENNature Communications, Vol 9, Iss 1, Pp 1-14 (2018) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Science Q |
spellingShingle |
Science Q Hans D. Brightbill Eric Suto Nicole Blaquiere Nandhini Ramamoorthi Swathi Sujatha-Bhaskar Emily B. Gogol Georgette M. Castanedo Benjamin T. Jackson Youngsu C. Kwon Susan Haller Justin Lesch Karin Bents Christine Everett Pawan Bir Kohli Sandra Linge Laura Christian Kathy Barrett Allan Jaochico Leonid M. Berezhkovskiy Peter W. Fan Zora Modrusan Kelli Veliz Michael J. Townsend Jason DeVoss Adam R. Johnson Robert Godemann Wyne P. Lee Cary D. Austin Brent S. McKenzie Jason A. Hackney James J. Crawford Steven T. Staben Moulay H. Alaoui Ismaili Lawren C. Wu Nico Ghilardi NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus |
description |
Clinical trials of BAFF blockade with belimumab have shown partial efficacy for the treatment of systemic lupus erythematosus (SLE), so other therapeutic options are required. Here, the authors present a new small molecule inhibitor that targets NIK with a similar efficacy to BAFF inhibition in two mouse models of SLE. |
format |
article |
author |
Hans D. Brightbill Eric Suto Nicole Blaquiere Nandhini Ramamoorthi Swathi Sujatha-Bhaskar Emily B. Gogol Georgette M. Castanedo Benjamin T. Jackson Youngsu C. Kwon Susan Haller Justin Lesch Karin Bents Christine Everett Pawan Bir Kohli Sandra Linge Laura Christian Kathy Barrett Allan Jaochico Leonid M. Berezhkovskiy Peter W. Fan Zora Modrusan Kelli Veliz Michael J. Townsend Jason DeVoss Adam R. Johnson Robert Godemann Wyne P. Lee Cary D. Austin Brent S. McKenzie Jason A. Hackney James J. Crawford Steven T. Staben Moulay H. Alaoui Ismaili Lawren C. Wu Nico Ghilardi |
author_facet |
Hans D. Brightbill Eric Suto Nicole Blaquiere Nandhini Ramamoorthi Swathi Sujatha-Bhaskar Emily B. Gogol Georgette M. Castanedo Benjamin T. Jackson Youngsu C. Kwon Susan Haller Justin Lesch Karin Bents Christine Everett Pawan Bir Kohli Sandra Linge Laura Christian Kathy Barrett Allan Jaochico Leonid M. Berezhkovskiy Peter W. Fan Zora Modrusan Kelli Veliz Michael J. Townsend Jason DeVoss Adam R. Johnson Robert Godemann Wyne P. Lee Cary D. Austin Brent S. McKenzie Jason A. Hackney James J. Crawford Steven T. Staben Moulay H. Alaoui Ismaili Lawren C. Wu Nico Ghilardi |
author_sort |
Hans D. Brightbill |
title |
NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus |
title_short |
NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus |
title_full |
NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus |
title_fullStr |
NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus |
title_full_unstemmed |
NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus |
title_sort |
nf-κb inducing kinase is a therapeutic target for systemic lupus erythematosus |
publisher |
Nature Portfolio |
publishDate |
2018 |
url |
https://doaj.org/article/c1b21708fc0a4c58b4c58242d9d32c50 |
work_keys_str_mv |
AT hansdbrightbill nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT ericsuto nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT nicoleblaquiere nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT nandhiniramamoorthi nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT swathisujathabhaskar nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT emilybgogol nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT georgettemcastanedo nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT benjamintjackson nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT youngsuckwon nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT susanhaller nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT justinlesch nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT karinbents nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT christineeverett nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT pawanbirkohli nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT sandralinge nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT laurachristian nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT kathybarrett nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT allanjaochico nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT leonidmberezhkovskiy nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT peterwfan nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT zoramodrusan nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT kelliveliz nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT michaeljtownsend nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT jasondevoss nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT adamrjohnson nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT robertgodemann nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT wyneplee nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT carydaustin nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT brentsmckenzie nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT jasonahackney nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT jamesjcrawford nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT steventstaben nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT moulayhalaouiismaili nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT lawrencwu nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus AT nicoghilardi nfkbinducingkinaseisatherapeutictargetforsystemiclupuserythematosus |
_version_ |
1718386742523854848 |